Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Wang, Bing ^a   Yu, Xiu Chun ^a   Xu, Song Feng ^a   Xu, Ming ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

apoptosis; etoposide; Osteosarcoma; paclitaxel; PLGA NP

Indexed keywords

CELL CULTURE; CELL DEATH; CELLS; COPOLYMERS; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG PRODUCTS;

CHEMOTHERAPEUTIC DRUGS; ETOPOSIDE; OSTEOSARCOMA; PACLITAXEL; PLGA NP; POLYMERIC NANOPARTICLES; SPHERICAL MORPHOLOGIES; THERAPEUTIC STRATEGY;

NANOPARTICLES;

ETOPOSIDE; NANOPARTICLE; PACLITAXEL; POLY(LACTIC CO GLYCOLIC ACID) NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CYTOTOXICITY; DRUG UPTAKE; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; SUSTAINED DRUG RELEASE; BONE NEOPLASMS; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; HUMAN; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DRUG CARRIERS; ETOPOSIDE; HUMANS; LACTIC ACID; NANOPARTICLES; OSTEOSARCOMA; PACLITAXEL; POLYGLYCOLIC ACID;

EID: 84926386660     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0086-4     Document Type: Article

References (28)

1. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423-36.
2. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006;23:367-80.
3. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-52.
4. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705-18.
5. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431-45.
6. Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366-73.
7. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med. 2011;364:985-7.
8. Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, Huang SY, et al. Simultaneous delivery of siRNA and paclitaxelviaa "Two in-One" micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5:1483-94.
9. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing irradiation in antitumour therapy. Nature. 1998;394:287-91.
10. Lane D. Designer combination therapy for cancer. Nat Biotechnol. 2006;24:163-4.
11. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today. 2001;6:1153-64.
12. Herbst RS, Khuri FR. Mode of action of docetaxel-a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407-15.
13. Steward WP, Thatcher N, Edmundson JM, Shiu W, Wilkinson PM. Etoposide infusions for treatment of metastatic lung cancer. Cancer Treat Rep. 1984;68:897-9.
14. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005;5:363-72.
15. Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1:323-34.
16. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27:659-66.
17. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010;107:17939-94.
18. Seju U, Kumar A, Sawant K. Development and evaluation of olanzapineloaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7:4169-76.
19. Shimada T, Ueda M, Jinno H. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 2009;29:1009-14.
20. Perez EA, Buckwalter CA. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol. 1998;41:448-52.
21. Singh A, Talekar M, Tran TH, Samanta A, Sundaramb R, Amiji M. Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy. J Mater Chem B. 2014;2:8069.
22. Ramasamy T, Kim JH, Choi JY, Tran TH, Choi HG, Yong CS, et al. pH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy. J Mater Chem B. 2014;2:6324.
23. Blechinger J, Bauer AT, Torrano AA, Gorzelanny C, Bräuchle C, Schneider SW. Uptake kinetics and nanotoxicity of silica nanoparticles are cell type dependent. Small. 2013;9:3970-80.
24. Pu Y, Chang S, Yuan H, Wang G, He B, Gu Z. The anti-tumor efficiency of poly(L-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores. Biomaterials. 2013;34:3658-66.
25. Wei R, Cheng L, Zheng M, Cheng R, Meng F, Deng C, et al. Reduction responsive disassemblable core-cross-linked micelles based on poly (ethylene glycol)-b-poly (n-2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release. Biomacromolecules. 2012;13:2429-38.
26. Anitha A, Deepa N, Chennazhi KP, Lakshmanan VK, Jayakumar R. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochim Biophys Acta. 1840;2014:2730-43.
27. Park JS, Han TH, Lee KY, Han SS, Hwang JJ, Moon DH, et al. N-acetyl histidineconjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J Control Release. 2006;115:37-45.
28. Ramasamy T, Ruttala HB, Choi JY, Tran TH, Ku SK, Choi HG, et al. Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan. Chemical Communications. 2015;51:5758.